ScholarIQanswers from OpenAlex

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis

PaperCitations, authors & open-access status

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis have?

ScholarIQcitation count

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis has 285 citations in the OpenAlex counts ScholarIQ stores.

When was Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis published?

ScholarIQyear

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis has 2015 year in the ScholarIQ index.

What is the open-access status of Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis?

ScholarIQoa status

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis has bronze oa status in the ScholarIQ index.

What is the DOI of Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis?

ScholarIQdoi

The DOI for Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis is on the source record.

What is the PMID of Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis?

ScholarIQpmid

The PMID for Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis is on the source record.

What is the OpenAlex record for Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis?

ScholarIQopenalex

The OpenAlex for Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial